Updates in the Treatment of EGFR-Mutant NSCLC: Highlights from WCLC and ESMO 2023
In the context of recent data updates from the WCLC and ESMO 2023 meetings, expert oncologists discuss therapy for non-small cell lung cancer with a focus on EGFR-mutant disease.
EP. 1: Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies
November 13th 2023Insights into diagnosing EGFR-mutant lung cancer and explores evolving first-line treatment strategies, incorporating recent developments, combinations, and clinical trial data, while addressing challenges in testing and patient management.
EP. 2: Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
November 13th 2023Explore significant updates in the field of EGFR-mutant lung cancer treatment, focusing on the introduction of combination therapy in the first-line setting, including the FLAURA2., MARIPOSA, and RAMOSE trials, offering improved progression-free survival and potential implications for patient care.
EP. 3: Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
November 20th 2023Experts consider the influence of combination therapies on EGFR-mutant lung cancer treatment, including the impact on central nervous system (CNS) response, challenges in CNS metastases management, and the potential alternatives to whole-brain radiation.
EP. 4: EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data
November 20th 2023Shared insight into the complexities in treating EGFR mutant lung cancer during the second-line therapy phase, including safety profiles of different treatment regimens, managing toxicities, and ongoing research to improve patient outcomes.
EP. 5: Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
November 27th 2023Learn about the latest developments in the treatment of lung cancer, focusing on EGFR mutations, antibody-drug conjugates (ADCs), targeted therapies, and biomarker-driven approaches to improve patient outcomes in various stages of the disease.
EP. 6: EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
November 27th 2023Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies, clinical trial results, and the quest for first-line treatment options, providing valuable insights into managing this unique patient population.
